Potential of dihydropyrimidine dehydrogenase genotypes in personalising 5-fluorouracil therapy among colorectal cancer patients

• Main Authors: Ngow, Harris Abdullah, Lay , Kek Teh, Hamzah, Sharina, Hashim, Hazwanie, Bannur, Zakaria, Zakaria, Zainul Amiruddin, Hasbullani, Zakaria, John Kwong, Siew Shia, Henry, Fijeraid, Md Nor, Azmid, Zailani, Mohd, Prabu, Ramasamy, Suneet, S, Salleh, Mohd Zaki
• Format: Article
• Language: English
• Published: International Association of Therapeutic Drug Monitoring and Clinical Toxicology 2011
• Subjects: RC Internal medicine
• Online Access: http://irep.iium.edu.my/43026/1/potential.pdf; http://irep.iium.edu.my/43026/; http://journals.lww.com/drug-monitoring/pages/default.aspx

Background: Dihydropyrimidine dehydrogenase (DPD) is a pyrimidine catabolic enzyme involved in the initial and rate-limiting step of the catabolic pathway of toxic metabolites of 5-fluorouracil (5-FU). Several studies have reported that deficiency of DPD and polymorphisms of its gene are related to...